a b s t r a c t CXCR4 is a chemokine receptor which has been shown to be exploited by various tumors for increased survival, invasion, and homing to target organs. We developed a one step radiosynthesis for labeling the CXCR4-specific antagonist AMD3100 with Cu-64 to produce 64 Cu-AMD3100 with a specific activity of 11.28 Ci/lmol (417 GBq/lmol) at the end of radiosynthesis. Incorporation of Cu(II) ion into AMD3100 did not change its ability to inhibit cellular migration in response to the (only) CXCR4 ligand, SDF-1/CXCL12. 64 Cu-AMD3100 binding affinity to CXCR4 was found to be 62.7 lM. Biodistribution of 64 Cu-AMD3100 showed accumulation in CXCR4-expressing organs and tissues, a renal clearance pathway, and an anomalous specific accumulation in the liver. We conclude that 64 Cu-AMD3100 exhibits promise as a potential PET imaging agent for visualization of CXCR4-positive tumors and metastases and might be used to guide and monitor anti-CXCR4 tumor therapy.
Introduction
Chemokines are small (8-14 kDa), mostly basic, structurally related peptides, that serve as chemotactic factors to guide migratory cells within an organism. 1 Chemokines mediate their effects through a subfamily of seven transmembrane domain, G proteincoupled receptors. The ability of chemokines to control cell trafficking is essential in various physiological processes. [2] [3] [4] [5] [6] [7] More than forty chemokines [3] [4] [5] [6] [7] and nineteen chemokine receptors (CKRs) have been identified in humans. Chemokines play an essential role in the recruitment and activation of cells of the immune system. 3 In addition, there is strong evidence that tumor-derived chemokines are responsible for recruitment of host cells that support tumor progression, 8, 9 and CKRs were also shown to be involved in various tumor processes and metastasis.
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CXCR4 was originally discovered as the putative co-receptor for entry of T-tropic, but not M-tropic, strains of HIV-1 viruses into CD4 + T cells; 11, 12 and extensive research has elucidated the functions of this receptor. CXCR4 has been highly conserved during evolution and can be detected in a diverse range of cells, including peripheral blood lymphocytes and monocytes, mast cells, adult CD34 + bone marrow progenitor cells, endothelial cells, intestinal and alveolar epithelial cells, astrocytes, microglia, and neurons. 11, [13] [14] [15] [16] [17] The native ligand for CXCR4 is the chemokine stromal cell-derived factor-1 (SDF-1), also known as CXCL12. Like CXCR4, SDF-1 has been highly conserved during evolution. SDF-1 is expressed constitutively in a number of tissues including liver, lungs, lymph nodes, adrenal glands and bone marrow. Together, the SDF-1/ CXCR4 ligand-receptor pair constitutes an axis that has been shown to be involved in directing cells to organ sites with high levels of SDF-1 expression, suggesting that this interaction plays a key role in the chemotaxis, retention, and homing of hematopoietic cells during homeostasis, and in the process of cancer metastases. 18, 19 In addition, the CXCR4/SDF-1 axis plays a fundamental role in the migration of progenitor cells during embryonic development of the cardiovascular, hemopoietic, and central nervous systems, [20] [21] [22] [23] [24] as revealed through studies of both CXCR4 and SDF-1 knockout mice. [24] [25] [26] On the other hand, CXCR4 and SDF-1 axis have also been shown, as noted above, to be exploited by HIV infection and to have roles in other disease processes such as cancer cell metastasis, leukemia progression, rheumatoid arthritis, and pulmonary fibrosis. [27] [28] [29] [30] [31] 10 More than 23 different human tumors, including breast, prostate, lung, ovarian, pancreatic, esophageal, colorectal, renal carcinoma, melanoma, neuroblastoma, and osteosarcoma, overexpress CXCR4. [21] [22] [23] 32, 29, 9, 33 As one example of the possible importance of CXCR4 in cancer, Marchesi et al. have shown that CXCR4 stimulates pancreatic tumor cells motility and invasion, and promotes their survival and proliferation. 34 Similarly, CXCR4 expression by tumor cells was shown to contribute to tumor growth, vascularization, and metastasis in prostate cancer xenografts in mice. 35 In accord with these data, inhibition of CXCR4 resulted in lower metastatic loads in the bones of mice injected with prostate cancer cells. 36 Up-regulation of CXCR4 has been also implicated in the pathogenesis of various neuro-degenerative and neuro-inflammatory diseases. [37] [38] [39] CXCR4 inhibitors, both peptide-based and small molecules, have been developed as potential therapeutics. AMD3100 (Fig. 1 , compound 1), a bicyclam molecule, in which the two cyclam moieties are linked by a 1,4-phenylenebis(methylene)-bridge ( Fig. 1) , [40] [41] [42] [43] [44] has been identified as a specific inhibitor of CXCR4. AMD3100 was originally developed as an inhibitor of HIV infection that worked by blocking the interaction of viral gp120s of some strains of HIV-1 with CXCR4 on CD4 T cells, and has been shown to block HIV infection in clinical trials. Clinical trials also demonstrated that 1 is an effective mobilizer of hematopoietic stem cells from the bone marrow (BM) in both healthy individuals and some individuals with cancer, [45] [46] [47] and is likely to enter clinical practice for this indication. Compound 1 was also found to inhibit the SDF-1-induced chemotaxis through CXCR4 by blocking migration of monocytic cells toward higher concentration of SDF-1, 48 suggesting that it might also be used to inhibit cancer metastasis. Positron emission tomography (PET), a non-invasive molecular imaging modality, uses short-lived positron-emitting bioprobes to obtain four-dimensional, quantitative determination of the distribution of radioactivity within the body. 49-51 64 Cu (t ½ = 12.7 h., b + 17.9%, electron capture 45%, b À 37.1%) can be used for PET imaging due to its positron emission and for radiotherapy due to its electron capture and b À emissions in cancer treatment. [52] [53] [54] [55] [56] [57] [58] [59] Previous attempts to image CXCR4 for single photon emission computed tomography (SPECT) have been reported. The CXCR4 peptide antagonist Ac-TZ14011 labeled with 111 In, accumulated in the spleen (8% ID/g), had high accumulation in the kidneys and liver, and displayed low accumulation in tumors (0.51% ID/ g). 60 SDF-1 has been labeled with Tc-SDF-1 was required to assess the accumulation in the myocardium; 0.6% ID/g accumulation was observed in the infracted myocardium compared with 0.1% ID/g in normal myocardium. 61 In this manuscript we describe a novel radiochemical synthesis of 64 Cu-AMD3100 (4) and its evaluation as a potential imaging agent of CXCR4 expression in a living organism. We describe binding and inhibitory properties of 64 Cu-AMD3100 (4) in vitro and/or in vivo. 
Material and methods

General methods
1-(4,8-Bis
This reaction was conducted as previously described. 40 To a solution of 2 (1.78 g, 3.64 mmol) in CH 3 CN (20 mL) were added a,a 0 -dibromoxylene (0.481 g, 1.82 mmol) and K 2 CO 3 (1.5 g, 10.9 mmol). The reaction was refluxed over night. After solvent evaporation, the crude product was extracted with CH 2 Cl 2 and H 2 O, dried over MgSO 4 , evaporated and purified on silica gel flash chromatography using gradient of CH 2 Cl 2 /MeOH as eluent, to give 3 as a white solid in a yield of 66% (2.6 g, 2.41 mmol). 1 This reaction was conducted as described elsewhere. 64 In brief, to a solution of 3 (1.1 g, 1.02 mmol) in 5 mL of methanol were added K 2 CO 3 (0.43 g, 3.1 mmol). The suspension was refluxed for 3 h. Then the reaction was cooled and toluene (10 mL) was added. The methanol was evaporated and MgSO 4 was added to the toluene suspension. The solution was filtered and toluene was concentrated to give 1 as a free base with a yield of 66% (0.34 g, 0.67 mmol). 2.4. Biology 2.4.1. Animals C57BL/6 mice were purchased from Taconic (Germantown, NY) and housed under specific pathogen free conditions. All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals on approved studies from the National Institutes of Health Institutional Animal Care and Use Committee.
Cells
Jurkat cells were purchased from the ATCC and grown in RPMI supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine and penicillin-streptomycin (Gibco, CA).
A single cell suspension of mouse splenocytes was prepared by disrupting a spleen and lysing red cells using ACK solution (Quality Biological, MD).
Transwell migration assays
600 lL of migration medium (RPMI supplemented with 1% fetal bovine serum) containing SDF-1 (PeproTech, NJ), at the concentration indicated, were placed into the lower chamber of a Costar 24-well transwell (Corning, NY). 10 5 Jurkat cells in 100 lL migration medium were placed into the upper chamber (pore size 5 lm) and cells were collected from lower chamber after 3 h of migration at 37°C, and counted by flow cytometry using counting beads. Control migrations were performed without the chemokine in the lower chamber.
Binding assay
Cells ( Cu-4 in a volume of 100 lL were injected through the tail vein of C57BL/6 mice. One, two and 6 h post injection, blood was drawn from the heart under anesthesia and the mice were sacrificed. Spleen, liver, muscle, kidney, mesenteric lymph nodes (LN), intestine and femurs were removed. BM was flushed from within the bones, and the remaining organs were weighed. All organs were assayed for radioactivity using a gamma counter ( 64 Cu source of known activity was imaged to obtain KBq of 64 Cu per counts per seconds for the imaging system (calibration factor). Then, every ROI (counts per second per cubic centimeter) was multiplied by this factor and divided by injected activity.
Flow cytometry
Jurkat cells (10 6 in 100 lL of PBS supplemented with 4% FBS)
were blocked with serum for five min on ice and then stained with PE-conjugated anti-human CXCR4 or isotype control (R&D Systems, MN). Cells were acquired on an LSRII (BectonDickinson, CA) and analyzed using FlowJO (Tree Star, OR).
Results and discussion
1 is a symmetrical bicyclam that is a highly specific CXCR4 antagonist and that can bind to metal ions such as Cu(II). 66 It was demonstrated that a complex between 1 and metal ions such as Ni(II), Zn(II) and Cu(II) improved the interaction of the cyclam complex with a carboxylate group of an aspartate residue within the binding pocket of CXCR4. 66 There are several synthetic routes to obtain 1 which involves optimization of reaction conditions such as pH, 67 temperature, and concentration. 63 Other methods involve blocking of amino groups using phosphorus 68, 69 or metal-tricarbonyl, 70 but involve the use of anhydrous material and undesirable solvents. In addition, a direct synthetic route for 1 without the need of protecting groups, 71 requires more synthetic steps and no improvement of the yield. The synthesis of 1, as a free base, included three steps (Fig. 2) ; (i) protecting on the cyclam (ii) bis-alkylation-dimerization and (iii) deprotection. 63, 40 The protection of the amine on the cyclam ring was done similarly to the procedure of Yang et al., 63, 72 using four equivalents of ethyl trifluororacetate (EtOTFA) as a selective acetylation agent. However, we obtained a mixture of 60% fully protected cyclam and only 40% of the desired product, 2, which contains one free amine as established by GCMS and NMR. Hence, we modified the synthesis and used only three equivalent of EtOTFA under the same reaction conditions as described in the experimental section, and we succeeded in obtaining 2 with a conversion >99% and 86% yield. The dimerization of two cyclam rings and the de-protection of the TFA groups to furnish 1 as a free base were done as previously published.
40,64
1 was used for the preparation of cold standard, 4, containing Cu(II) ion (Fig. 3) , and as a precursor for the radiosynthesis with 64 Cu (Fig. 3) . The incorporation of a single Cu(II) ion into 1 was assured by using 1 equiv of Cu(OAc) 2 . The incorporation reaction was conducted in methanol; however, in order to obtain better solubility, Cu(OAc) 2 was first dissolved in a small volume of NH 4 OAc buffer (0.1-0.2 mL). The incorporation was verified using IR and elemental analysis.
The incorporation reaction was optimized for the smallest amount of substrate because we wished to avoid the need to remove excess unlabeled ligand (1). Cu into a TETA chelator. 52 Gerlach et al. demonstrated that incorporation of metal ions into 1 improved the binding affinity towards CXCR4, as measured by inhibiting binding of SDF-1 and anti-CXCR4 antibody. 66 In order to verify that incorporation of Cu(II) ion enhances the binding of 1 to CXCR4, we evaluated binding in Jurkat T cells. We established that the Jurkat T-cells express high levels of CXCR4 using flow cytometry (Fig. 5a) . The cells were then incubated with a constant amount of 64 Cu-4 and increasing concentrations of non-radioactive 4 for 1 h at rt (Fig. 5b) (Fig. 5c) . This is the first published result of homologous displacements for 1. Heterologous displacement of radiolabeled antibody with 4
showed lower IC 50 of 0.1 lM by Gerlach et al., 66 and an IC 50 of 15.2 lM was reported by Gupta et al., which was done by competition of 1 with 125 I-SDF-1 using HL-60 cells. 73 In order to verify that the CXCR4 inhibitory characteristics of 4 are not affected by the incorporation of Cu(II) ion, we evaluated the ability of 64 Cu-4 to inhibit Jurkat cells migration towards SDF-1.
Migration was tested through 5 lm pore membrane in a standard assay format. We used SDF-1 in the lower wells at 100 ng/mL, the (Fig. 6 ). This result indicates that 4 retain the ability to inhibit SDF-1-induced chemotaxis through CXCR4.
A comparison between the binding affinity of 4 towards CXCR4, versus its migration inhibition, revealed a 1000-fold discrepancy between the binding as measured by homologous displacement and functional activity. A similar discrepancy has been observed between activity of AMD3100 and heterologous displacement of SDF-1. 66 Another interesting observation was reported for a differ- ing of CCL5 through binding deep in the main ligand binding pocket. 74 Although we cannot explain these discrepancies, we postulate that AMD3100 may show high-affinity interactions to the SDF-1-bound form of CXCR4 (positive co-operativity), producing a nonsignaling conformation.
The biodistribution of 64 Cu-4 was analyzed in immune competent C57BL/6 mice using both PET scans in live animals and organ dissection and gamma counting. Since multiple immune cells express CXCR4, we would expect the tracer to accumulate in immune-related organs such as the spleen, lymph nodes and bone marrow. Mice were divided into six groups: three groups were injected (i.v.) only with 64 Cu-4 and sacrificed after 1, 2 and 6 h. A forth and fifth groups were designed to test the specific binding of 4 in vivo and was co-injected with excess of cold tracer and sacrificed 2 or 6 h post injection. The sixth group was injected with SDF-1 to evaluate specific binding of 64 Cu-4 to CXCR4, and sacrificed after 2 h. Spleen, intestine, LN, femoral BM, blood, liver, muscle and kidney were removed for gamma-counting (Fig. 7) . Cu-4, measured by percent ID/g of tissue, was detected after 1 h in the liver (41%) and kidneys (10%). High accumulation of 64 Cu-4 was also observed in immune related organs; spleen (13%), BM (14%) and LN (10%). 64 Cu-4 uptake was low in blood and muscle (1.7% and 0.3%, respectively). 2 h-post injection there were significant changes in 64 Cu-4 accumulation only in the blood which was reduced to <1%, and a slight increase in the liver to 49% (Fig. 7a) . A slight increase of 64 Cu-4 was observed in the spleen, LN, liver and BM 6 h post injection (Fig. 7a) . Co-injection of excess of non-labeled 4 resulted in reduced accumulation of 64 Cu-4 in all immune related organs by 60-80% in comparison to the accumulation after 2 or 6 h ( Fig. 7b and c) . Surprisingly, the accumulation of 64 Cu-4 in the liver was also reduced by 79% and 74% after 2 and 6 h respectively, which suggests specific binding of 4 in the liver. There was a corresponding increase in accumulation of 64 Cu-4 in the kidneys, presumably due to a reduction in specific binding and enhanced renal clearance. 75 Injection of 10 lg SDF-1 20 min prior to and together with the 64 Cu-4 reduced the accumulation of 64 Cu-4 in the liver, BM and slightly in the spleen (Fig. 7b) . The lower reduction of the tracer accumulation after excess of SDF-1 injection in comparison to excess of 4 could be due to differences in distribution and/or pharmaco-kinetics of the SDF-1 protein vs. the small molecule AMD3100. In addition, the possible binding of SDF-1 to glycosaminoglycans and heparin sulphate invivo might reduce the bioavailability of SDF-1 to bind CXCR4.
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CXCR4 expression in the liver is reportedly limited to sinusoidal endothelial cells 77 , oval cells, 78, 79 and to immune cells, 80 Tc labeled SDF-1 did not accumulate in the liver. 61 Hence, the specificity of 1 for CXCR4 should be re-examined in binding assays using liver membrane preparations. The differences between our biodistribution results and other reported biodistribution of labeled CXCR4 ligands SDF-1 61 and
Ac-TZ14011, 60 might be explained by the different pharmacokinetics of small protein and small peptide, respectively, and the pharmaco-kinetics of a small molecule such as AMD3100. In addition to biodistribution experiments, mice were also scanned with ATLAS, to visualize the uptake in the various organs. The rapid renal clearance of 64 Cu-4 resulted in high accumulation of 64 Cu-4 in the bladder within 2 h (Fig. 8b) . As was revealed by organ analyses, there was high accumulation of 64 Cu-4 in the liver, kidney and spleen. Blocking with excess of non-radioactive 4 reduced the uptake in the spleen and liver to undetectable levels, and increased the accumulation in the kidneys, in accordance with the biodistribution results ( Fig. 8a and b) . In addition, to verify that the activity was due to accumulation of 64 Cu-4 rather than free 64 Cu, mice were scanned after injection of free 64 Cu. The uptake of the free isotope was in the liver and intestine ( Fig. 8a and b) . There was no uptake in the spleen, and low accumulation in the bladder. These results indicate that free 64 Cu does not accumulate in immune organs.
Biodistribution and PET scans revealed that 
Conclusions
We prepared 64 Cu-4, a potent CXCR4 antagonist, in high radiochemical yield and with high radiochemical purity. 64 Cu-4 was as potent as 1 in inhibiting the activity of CXCR4. Thus, we expected no alteration in in vivo characteristics of 64 Cu-4 versus 1, including binding to CXCR4 and acting as a CXCR4 antagonist. Biodistribution studies revealed uptake by organs and tissues involved in the immune system of mice as well as in the liver. Uptake in the liver, which although specific, may have a CXCR4-independent component and may detract from the usefulness of this radiotracer for imaging cancers in the liver. We conclude that 64 Cu-4 might be useful for discriminating CXCR4 positive and negative tumors, and for directing the use and monitoring the effectiveness of CXCR4-targeted therapies.
